WO2004065382A1 - Diazepanes derivatives useful as lfa inhibitors - Google Patents

Diazepanes derivatives useful as lfa inhibitors Download PDF

Info

Publication number
WO2004065382A1
WO2004065382A1 PCT/EP2004/000514 EP2004000514W WO2004065382A1 WO 2004065382 A1 WO2004065382 A1 WO 2004065382A1 EP 2004000514 W EP2004000514 W EP 2004000514W WO 2004065382 A1 WO2004065382 A1 WO 2004065382A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
compound
methyl
oxo
lfa
Prior art date
Application number
PCT/EP2004/000514
Other languages
French (fr)
Inventor
Berndt Oberhauser
Gottfried Meingassner
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0301561A external-priority patent/GB0301561D0/en
Priority claimed from GB0323976A external-priority patent/GB0323976D0/en
Priority to MXPA05007846A priority Critical patent/MXPA05007846A/en
Priority to NZ540867A priority patent/NZ540867A/en
Priority to JP2006500007A priority patent/JP4644655B2/en
Priority to BR0406884-0A priority patent/BRPI0406884A/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to AU2004205504A priority patent/AU2004205504B2/en
Priority to CA002509764A priority patent/CA2509764A1/en
Priority to US10/541,183 priority patent/US7419976B2/en
Priority to EP04704212A priority patent/EP1590342A1/en
Publication of WO2004065382A1 publication Critical patent/WO2004065382A1/en
Priority to NO20053911A priority patent/NO20053911L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to pharmaceutically active diazepanes.
  • the present invention provides a compound of formula
  • R-i is (C )alkyl, e.g. methyl
  • R 2 is unsubstituted (C 1 _ )alkyl, e.g. methyl, or (d ⁇ )alkyl substituted by unsubstituted or substituted
  • - (C 6 .i 8 )aryl e.g. phenyl, annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. which aryl or aryl annelated with heterocyclyl is one or morefold substituted by
  • R 3 is (C 6 . 8 )aryl, e.g. phenyl, one or morefold substituted by
  • heterocyclyl having 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. aromatic heterocyclyl, such as pyrimidinyl.
  • R 2 is methyl or methyl substituted by
  • phenyl one or morefold substituted by halogen, cyano, amino, dimethylamino, carboxyCC ⁇ alkylcarbonylamino, amino(C 1 . 2 )alkylcarbonylamino, (C 2 ⁇ )alkylenecarbonylamino, heterocyclylcarbony C ⁇ alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, O, such as piperazinyl, morpholinyl,
  • R 3 is phenyl one or morefold, e.g. 1- to 3-fold, substituted by
  • heterocyclyl including aromatic, having 6 ring members and 2 nitrogen heteroatoms, such as pyrimidinyl.
  • the present invention provides a compound of formula I wherein
  • R 2 is methyl substitued by quinolin-6-yl
  • R 3 is phenyl one or morefold, e.g. 1- or 2-fold, substituted by
  • halogen e.g. fluoro, chloro, bromo
  • haloCC t ⁇ alkyl, e.g. CF 3
  • - haloCC ⁇ alkoxy e.g. OCF 3
  • the present invention provides a compound of formula I wherein
  • R 2 is methyl substituted by benzo[1,3]dioxol-5-yl
  • R 3 is phenyl one or morefold, e.g. 1- or 2-fold, substituted by
  • halogen e.g. fluoro or chloro
  • the present invention provides a compound of formula I wherein
  • R 2 is methyl substituted by phenyl or methyl substituted by phenyl one or morefold, e.g. 1 to 3-fold, substituted by
  • halogen e.g. chloro
  • heterocyclylcarbonyHC t alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, O, S, preferably from N or O, e.g. piperazin-1-yl or morpholin-4-yl,
  • R 3 is phenyl substituted one or morefold by
  • halogen e.g. chloro or fluoro
  • the present invention provides a compound of formula I wherein
  • R 3 is phenyl substituted by halogen, e.g. chloro.
  • the present invention provides a compound selected from the group consisting of
  • N-(4- ⁇ 2-[4-(1 -Carbamoyl-2-naphthalen-1 -yl-ethyl)-7-methyl-3-oxo-2-(3-trifluoromethyl- phenyl)-[1,4]diazepan-1-yl]-2-oxo-ethyl ⁇ -phenyl)-succinamic acid e.g. N-(4- ⁇ 2-[(2S,7R)-4-
  • the present invention provides a compound of formula I which is a compound of formula
  • the present invention provides (R)-2[(3S,5R)-4-(2-Benzo[1 ,3]dioxol-5-yl- acetyl)-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepam-1 -yl]-3-naphthalen-1 -yl- propionamide.
  • - alkyl includes linear or branched (C ⁇ )alkyl, such as (C M )alkyl, e.g. (C ⁇ alkyl, including unsubstituted or substituted alkyl, e.g. alkyl substituted by groups which are conventional in organic chemistry, e.g. halogen, OH, NH 2 or haloCd-eJalkyl,
  • - haloalkyl includes halo(C ⁇ . 6 )alkyl, such as haloCC ⁇ alkyl, e.g. halo(C ⁇ _ 2 )alkyl, wherein one or more halogen(s) is (are) present in the alkyl group, preferably -CF 3 ,
  • - halogen includes fluoro, chloro, bromo, iodo, e.g. fluoro, chloro, bromo, preferably fluoro or chloro,
  • - amino includes unsubstituted and substituted amino, e.g. amino substituted by (C t - ⁇ alkylamino, d C ⁇ alkylamino and amino substituted by acyl,
  • - acyl includes acyl, having 1 to 12 carbon atoms altogether, e.g. such as carboxy(C ⁇ _ 3 )alkylcarbonyl, aminoCC ⁇ alkylcarbonyl, such as amino- (C ⁇ - 3 )alkylcarbonyl, (C ⁇ alkenylcarbonyl or heterocyclylcarbony C ⁇ alkylcarbonyl, wherein heterocyclyl has 5 or 6 ring members and 1 to 4 heteroatoms, preferably 1 or 2 heteroatoms, selected from N, O, S, preferably N, O, e.g. piperazinyl or morpholinyl,
  • heterocyclyl includes heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, preferably N, O, such as alicyclic and aromatic heterocyclyl, e.g. heterocyclyl having 6 ring members and 1 to 2 heteroatoms selected from N, O, e.g. piperazinyl, morpholinyl, pyrimidinyl,
  • - aryl includes (C 6 - ⁇ 8 )aryl, e.g. phenyl, and (C 6 .i 8 )aryl, e.g. phenyl, annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, preferably N, O, e.g. heterocyclyl having 5 ring members and 2 heteroatoms selected from N, O, preferably benzo(1 ,3)dioxol-4-yl, benzo(1,3)dioxol-5-yl,quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl.
  • a compound of the present invention includes a compound in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a salt and in the form of a solvate.
  • a compound of the present invention in free form may be converted into a corresponding compound in the form of a salt; and vice versa.
  • a compound of the present invention in free form or in the form of a salt and in the form of a solvate may be converted into a corresponding compound in free form or in the form of a salt in unsolvated form; and vice versa.
  • the present invention provides a compound of the present invention in the form of a salt.
  • a salt of a compound of the present invention includes a pharmaceutically acceptable salt, e.g. including a metal salt or an acid addition salt.
  • Metal salts include for example alkali or earth alkali; acid addition salts include salts of a compound of formula I with an acid, e.g. acetic acid, trifluoroacetic acid, hydrochloric acid.
  • a compound of the present invention may exist in the form of isomers and mixtures thereof; e.g. optical isomers, diastereoisomers, cis/trans isomers.
  • a compound of the present invention may e.g. contain asymmetric carbon atoms and may thus exist in the form of diastereoisomeres and mixtures thereof or enantiomers or mixtures thereof, e.g. racemates.
  • the groups R ⁇ R 3 and the group naphthylmethyl in position * in a compound of formula I may be in the (R)- or in the (S)-configuration, e.g. including mixtures therof.
  • the naphthylmethyl group and Rt in a compound of formula I both are in the (R)- configuration and R 3 is in the (S)-configuration.
  • Isomeric mixtures may be separated as appropriate, e.g. according, such as analogously, to a method as conventional, to obtain pure isomers.
  • the present invention includes a compound of the present invention in any isomeric form and in any isomeric mixture.
  • Any compound described herein, e.g. a compound of the present invention, may be prepared as appropriate, e.g. according, e.g. analogously, to a method as conventional, e.g. or as specified herein.
  • Starting materials are known or may be prepared according, e.g. analogously, to a method as conventional or as described herein.
  • the present invention provides a process for the preparation of a compound of the present invention comprising A) reacting a compound of formula
  • - condensing agent e.g. a carbodiimide
  • a base e.g. an amine, such as diidopropylethylamine or dimethylaminopyridine
  • organic solvent e.g. polar organic solvent, such as N,N-dimethylformamide, optionally deprotecting, and optionally further reacting, to obtain a compound of formula I and isolating a compound of formula I,
  • An optionally protected group R 2 of formula III e.g. includes phenyl substituted by an amine.
  • Such amine may be protected by an appropriate protection group, e.g. including tert- butoxycarbonyl (Boc), which protecting group may be removed after reaction of a compound of formula II with a compound of formula III to obtain a free amine group.
  • Further reacting e.g. includes alkylating or acylating such amine group as appropriate, e.g. according, e.g. analogously, to a method as conventional.
  • functional groups in an intermediate of formula II or of formula IV (starting materials), functional groups, if present, optionally may be in protected form or in the form of a salt, if a salt-forming group is present.
  • Protecting groups, optionally present, may be removed at an appropriate stage, e.g. according, e.g. analogously, to a method as conventional
  • a compound of formula I thus obtained may be converted into another compound of formula I, e.g. or a compound of formula I obtained in free form may be converted into a salt of a compound of formula I and vice versa.
  • the above reaction A) is a an amine acylation reaction and may be carried out as appropriate, e.g. according, e.g. analogously, to a method as conventional or as described herein.
  • the above reaction B) is a cross coupling reaction and may be carried out as appropriate, e.g. according, e.g. analogously, to a method as conventional or as described herein.
  • the compounds of the present invention exhibit valuable pharmacological properties, e.g. by mediating, such as inhibiting, the activity of LFA-1/ICAM-1 , LFA-1 /ICAM-2, LFA- /ICAM-3 or LFA-1/JAM-1 interactions and thus mediating, e.g. inhibiting inflammation, e.g. as indicated in in vitro and in vivo TEST SYSTEMS herein and are therefore indicated for therapy.
  • the assay determines the binding of soluble human ICAM-1 to immobilized human LFA-1.
  • LFA-1 is purified from JY cells, a human lymphoblastoid B cell-line, by immunoaffinity chromatography analogously as described by Dustin et al., J. Immunol. 148, 2654-2663,
  • ICAM-1 mouse CK fusion protein (ICAM-1) is produced using the baculovirus system as described by Weitz-Schmidt et al., Anal. Biochem. 238,184-190, 1996.
  • Purified LFA-1 is diluted 1 :20 in phosphate buffered saline (PBS) containing 2 mM MgCI 2 , pH
  • Streptavidin- peroxidase diluted 1:5000 in assay buffer is added and incubated for 45 min at 37°. Plates are washed with assay buffer and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt substrate solution is added to each well. The reaction is stopped after 20 minutes and bound ICAM-1 is determined by measuring the optical density at 405 nm in a microplate reader.
  • the compounds of the present invention exhibit activity, e.g. the compounds of the present invention inhibit adhesion of LFA-1 to ICAM-1 with an IC 50 ⁇ 50 ⁇ M, preferably 0.05 to 50 ⁇ M.
  • the compounds of examples 13 and 14 are preferred compounds of the present invention and show IC 50 values of 0.43 or 0.09 ⁇ M, respectively, in this assay.
  • compounds of formula I, wherein R 3 is substituted phenyl show higher IC 50 values in such LFA-1 in vitro TEST SYSTEM than compounds of formula I, wherein R 3 is unsubstituted phenyl.
  • mice Groups of 8 female NMRI mice are sensitized on the shaved abdomen with 50 ⁇ l of oxazolone (2% in acetone) and challenged with 10 ⁇ l of 0.2% oxazolone on the inner surface of the right ear 7 days later.
  • the unchallenged left ears serve as normal controls and dermatitis is evaluated from the individual differences in auricular weights, which are taken as a measure of inflammatory swelling 24 hours after the challenge. Dermatitis is evaluated in test- and control groups.
  • the test groups are treated with the test compounds orally (2 hours after challenge), the controls are treated similarly with the vehicles alone.
  • the compounds are administered in an oil in H 2 O emulsion.
  • test- and the vehicle-treated control groups are statistically analysed by ANOVA followed by Dunnet T-test (normal distribution or data) or by H and U-test, respectively.
  • the compounds of the present invention inhibit the elicitation phase of allergic contact dermatitis.
  • compound of Example 14 has an inhibiting effect in this assay of >30% when administered p.o. at a dose of 0.03 mg/kg.
  • the compounds of the present invention are therefore expected to be useful in the treatment of diseases or disorders mediated by interactions of LFA-1 with its ligands involved in cell adhesion, migration and activation.
  • the compounds may be preferably useful for treatment of inflammatory conditions, allergic diseases or autoimmune diseases.
  • Examples are inflammatory injuries of the skin (psoriasis, eczemas, urticaria, acne, pyoderma gangrenosum, sun burns or toxic epidermal necrolysis), lung (adult respiratory distress syndrome, COPD), kidney (acute/chronic interstitial/glomerulonephritis), liver (acute/chronic hepatitis, granulomatous diseases), cardiovascular system (ischemia/reperfusion injuries, shock, arteriosclerosis, vasculitides), eye (conjunctivitis, keratitis) or gastrointestinal tract (Crohn's disease, ulcerative colitis).
  • Examples of allergic conditions are allergic contact dermatitis, atopic dermatitis or asthma.
  • Rheumatoid arthritis multiple sclerosis, (systemic) lupus erythematosus, Sjogren " syndrome, alopecia areata, uveitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa or myasthenia gravis are examples of auto-immune mediated conditions.
  • the compound of the present invention may also be used for prevention of acute and chronic rejection of allo- or xenografts, transplantation, host vs. graft or graft vs. host diseases, for the treatment of neoplastic diseases including metastasis of neoplastic or cancerous growth or cancer, AIDS and infectious diseases. Treatment includes prophylaxis.
  • the compound of the present invention may be preferably useful for treatment of psoriasis, rheumatoid arthritis, inflammatory bowel diseases (Crohn s disease, ulcerative colitis), (systemic) lupus erythematosus, atopic dermatitris, Sjogren' syndrom, rejection after transplantation and graft vs. host disease.
  • the compounds of the present invention are useful in the treatment of autoimmune diseases, e.g. rheumatoid arthritis, or of inflammatory diseases, e.g. psoriasis or atopic dermatitis, such as rheumatoid arthritis.
  • autoimmune diseases e.g. rheumatoid arthritis
  • inflammatory diseases e.g. psoriasis or atopic dermatitis, such as rheumatoid arthritis.
  • the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, satisfactory results are indicated to be obtained systemically at daily dosages of a compound of the present invention from about 0.1 mg/kg to about 100 mg/kg body weight.
  • An indicated daily dosage in the larger mammals, e.g. humans, is in the range from about 0.5 mg to about 500 mg (e.g. about 0,00625 mg/kg to about 6,25 mg/kg), conveniently administered, for example, in divided doses up to four times a day or in retard form.
  • the compounds of the present invention may be administered systemically or topically, by any conventional route, in particular enterally, e.g. orally, e.g.
  • Percutaneous administration via patches or other delivery systems may also be a possible route for prophylaxis or treatment of above diseases.
  • the present invention provides a compound of the present invention for use as a pharmaceutical, e.g. against diseases as indicated above, such as rheumatoid arthritis.
  • a compound of the present invention includes one or more, preferably one, compounds of the present invention, e.g. a combination of two or more compounds of the present invention.
  • the present invention provides the use of a compound of the present invention for the manufacture of a medicament, e.g. a pharmaceutical composition, for the treatment of a disease as indicated above, for example of diseases mediated by LFA- l/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions, e.g against inflammatory diseases, allergic conditions or autoimmune diseases, such as autoimmune diseases, e.g. psoriasis, asthma or rheumatoid arthritis.
  • a disease as indicated above, for example of diseases mediated by LFA- l/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions, e.g against inflammatory diseases, allergic conditions or autoimmune diseases, such as autoimmune diseases, e.g. psoriasis, asthma or rheumatoid arthritis.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present invention in association with at least one pharmaceutically acceptable excipient, e.g. including a carrier and/or diluent, e.g. including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers.
  • a pharmaceutically acceptable excipient e.g. including a carrier and/or diluent, e.g. including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers.
  • compositions may be manufactured according, e.g. analogously, to a method as conventional, e.g. by mixing a compound of the present invention with a pharmaceutically acceptable excipient, e.g. a carrier and/or diluent.
  • Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 1000 mg (e.g. from about 0.00125 mg/kg to about 12.5 mg/kg), e.g. 0.5 mg to 500 mg, such as e.g. 1 mg to about 125 mg of a compound of the present invention.
  • the compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt, e.g. an acid addition salt or metal salt; or in free form; optionally in the form of a solvate.
  • a pharmaceutically acceptable salt e.g. an acid addition salt or metal salt
  • the compounds of the present invention in the form of a salt exhibit the same order of activity as the compounds of the present invention in free form; optionally in the form of a solvate.
  • the present invention provides:
  • a method for treatment of diseases as indicated above e.g. inflammatory, allergic or autoimmune diseases, e.g. as indicated above, e.g. psoriasis, asthma, rheumatoid arthritis, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of the present invention.
  • an indicated daily dosage is in the range from about 0.01 g to about 1.0 g (e.g. from about 0,125 mg/kg to about 12,5 mg/kg), of a compound of the present invention; conveniently administered, for example, in divided doses up to four times a day.
  • a compound of the present invention may be administered by any conventional route, for example enterally, e.g. including nasal, buccal, rectal, oral, administration; parenterally, e.g. including intravenous, intramuscular, subcutanous administration; or topically; e.g. including epicutaneous, intranasal, intratracheal administration; e.g. in form of coated or uncoated tablets, capsules, injectable solutions or suspensions, e.g. in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops, sprays, or in the form of suppositories.
  • enterally e.g. including nasal, buccal, rectal, oral, administration
  • parenterally e.g. including intravenous, intramuscular, subcutanous administration
  • topically e.g. including epicutaneous, intranasal, intratracheal administration
  • injectable solutions or suspensions e.g
  • a compound of the present invention may be used for pharmaceutical treatment according to the present invention alone or in combination with at least one, e.g. one or more, other pharmaceutically active agents.
  • other pharmaceutically active agents e.g. include compounds active in immunomodulating regimens or other anti-inflammatory agents, e.g. for the treatment or prevention of inflammatory or allergic conditions, autoimmune disorders, or acute or chronic rejection of allo- or xenograft.
  • compounds of the present invention may be used in combination with cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g.
  • cyclosporin A cyclosporin G, FK-506, ASM 981 , rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin etc., corticosteroids, cyclophosphamide, azathioprene, methotrexate, FTY 720, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxyspergualine, immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45, or CD58 or their ligands, or other immunomodulatory compounds, e.g. CTLA4lg, or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including selectin antagonists and VLA-4 antagonists.
  • immunosuppressive monoclonal antibodies
  • Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation; kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e.g. with instructions for co- administration; and free combinations in which the pharmaceutically active agents are packaged separately, but instructions for simultaneous or sequential administration are given.
  • the compounds of the present invention are administered in combination with other immunosuppressive/immunomodulatory or anti-inflammatory active agents, e.g.for preventing or treating acute or chronic rejection or inflammatory or autoimmune disorders as hereinabove specified, dosages of the co-administered immunosuppressant, immunomodulatory or anti-inflammatory compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a cyclosporin, on the specific drug employed, on the condition being treated and so forth. In general comparable dosage ranges as indicated for the co-administration may be are appropriate.
  • the present invention provides a pharmaceutical composition according to the present invention, further comprising another pharmaceutically active agent.
  • a method for treatment of disorders or diseases as indicated above comprising co-administrating, e.g. concomitantly or in sequence, a therapeutically effective amount of at least one compound of the present invention and at least one second pharmaceutically active agent, said pharmaceutically active agent being selected from the group consisting of immunosuppressants, immunomodulatory or anti-inflammatory active agents, e.g. such as indicated above; and
  • a pharmaceutical combination e.g. a kit, for use in a method for treatment according to the present invention, comprising at least one compound of the present invention to be used concomitantly or in sequence with at least one immunosuppressant, immunomodulatory or anti-inflammatory active agent.
  • the kit may comprise instructions for concomitant administration or administration in sequence.
  • the present invention provides a compound of formula
  • R 1P is (C- jalkyl
  • R 2 p is (C ⁇ alkyl or -(CH 2 ) n -R p, wherein n is 1 , 2, 3 or 4 and
  • R 4P is unsubstituted or substituted
  • R 3P is substituted phenyl, e.g. one or morefold, wherein the substituents are selected from the group consisting of
  • substitutents are as indicated under "substituted phenyls" in the meaning of R 4P , e.g. in the form of a salt and/or solvate.
  • a compound of formula Phe-gly, wherein R 3 is as defined above, is dissolved in MeOH. 2 equiv. of NaHCO 3 and 1.2 equiv. of Boc-anhydride are added to the solution obtained and the suspension obtained is heated at 50° under stirring. From the mixture obtained solvent is evaporated and H 2 O and toluene are added. The phases obtained are separated and the organic phase obtained is extracted with 1N NaOH. The pH of the aqueous phase obtained is adjusted to pH 3 and the mixture obtained is extracted with EtAc. The organic phase obtained is dried, solvent is evaporated and racemic Boc-phenylglycine of formula A3, wherein R 3 is as defined above, is obtained. Ac. Amine acylation
  • a compound of formula A4, wherein R 3 is as defined above, is dissolved in TFA/H 2 O at 0°. The mixture obtained is stirred, quenched with H 2 O and solvent is evaporated. A diastereoisomeric mixture of a compound of formula A4, wherein the Boc-NH- group is deprotected is obtained and is dissolved in MeOH/H 2 O. The pH of the mixture obtained is adjusted to pH 5. 0.5 equiv.
  • a compound of formula A5, wherein j is as defined above, is treated with 1.7 equiv. of R COOH, wherein R 2 is as defined above, 1.3 equiv. of DIEA and 0.2 equiv. of HOAt in DMF.
  • the mixture obtained is heated to 35° and 1.7 equiv. of EDC are added and the mixture obtained is stirred for 15 hours at 35°.
  • solvent is evaporated, the evaporation residue obtained is dissolved in EtAc and extracted with 1N HCI and 5% NaHCO 3 solution.
  • the organic phase obtained is dried and solvent is evaporated.
  • a compound of formula A6 is obtained, which is optionally subjected to chromatography (e.g. silica gel, toluene/i-PrOH), in order for further purification, if desired.
  • PROCEDURE B e.g. silica gel, toluene/i-PrOH
  • the compound of example 22 is treated with 1.5 equiv. of N-Boc-beta-alanine, or N-Boc- glycine, respectively, 1.5 equiv. of EDC-HCI and 0.5 equiv. of DMAP in DMF at rt.
  • the mixture obtained is diluted with EtAc and 1 N HCI, two phases are obtained and are separated, the organic phase obtained is washed, dried and solvent is evaporated.
  • the evaporation residue obtained is dissolved in TFA/H O at 0°, stirred, diluted with dioxane and solvent is evaporated.
  • a residue obtained is subjected to RP-chromatography.
  • the compounds of example 31 and example 29, respectively, in the form of a trifluoroacetate are obtained.
  • the compound of example 30 is obtained.
  • the compound of example 31 is treated with an excess of CH 3 J in CH 2 CI 2 /K 2 CO 3 at rt. From the mixture obtained solvent is evaporated, the evaporation residue obtained is dissolved in MeOH/H 2 O and worked up by solid-phase extraction (C-18 cartridge, MeOH/H 2 O gradient).
  • the compound of example 27 is treated with 6 equiv. of morpholine and 2 equiv. of EDC-HCI in DMF at 0° for 4 hours at pH 8 (adjustment by addition of TFA).
  • the mixture obtained is diluted with EtAc and 1N HCI, two phases obtained are separated, the organic phase obtained is washed, dried and solvent is evaporated.
  • the compound of example 33 is obtained.
  • the compound of example 5 is treated with phenylboronic acid, or pyrimidine-5-boronic acid, respectively, in the presence of a catalytic amount of palladium tetrakistriphenylphosphine in dimethoxyethane/aqeous Na 2 CO -solution (6:1) at 130° for 10 minutes in a closed vessel.
  • the mixture obtained is diluted with EtAc, extracted at pH 4 with phosphate buffer and aqueous Na 2 CO solution, and, from the organic layer obtained, solvent is evaporated.
  • a compound of example 6, or 12b, respectively is obtained.
  • a compound of example 6 is treated with trifluoroacetic acid and the compound of example 6 is obtained in the form of a trifluoroacetate.
  • - 6 and 12b are prepared according to procedure G; - 26 and 27 are prepared according to procedure D;
  • Naphthalene-1 -carboxylic acid is dissolved in dry THF and 5 equiv. of borane dimethylsulfide complex are added. The mixture obtained is stirred at rt, diluted with EtAc, washed with 1N HCI and 5% NaHCO 3 solution, dried and solvent is evaporated.
  • (Naphthalene-1 -yl)-methanol is obtained, which is dissolved in CH 2 CI 2 .
  • To the solution obtained 1.5 equiv. of Dess-Martin reagent are added at rt.
  • the mixture obtained is diluted with EtAc, extracted with 1 N HCI and 5% NaHCO 3 -solution, dried and solvent is evaporated.
  • Naphthalene-1 -carboxaldehyde is obtained and dissolved with 1 equiv. of racemic-Boc- ⁇ -phosphonoglycine trimethylester in CH 2 CI 2 and 1.1 equiv. of DBU are added.
  • the mixture obtained is stirred at rt and treated in sequence with 1 N HCI and 5% NaHCO 3 solution.
  • the phases obtained are separated, the organic phase obtained is dried and solvent is evaporated.
  • 2-Boc-amino-3-(naphtha!ene-1- yl)-acrylic acid methyl ester (cis/trans mixture) is obtained, is dissolved in MeOH/H 2 O at pH 6.5 (phosphate buffer) and 20 w/w% of 10% Pd/C are added.
  • the mixture obtained is hydrogenated at rt and 50 bar, the catalyst is filtered off and from the filtrate obtained solvent is evaporated. Racemic naphythylalanine methylester is obtained, dissolved in methanolic NH 3 and stirred. The mixture obtained is subjected to extractive work up. Racemic naphythylalanine amide is obtained.
  • mice Groups of 8 female mice are sensitized epicutaneously with 50 ⁇ l of 2% oxazolone on the shaved ventral abdomen (day 1) and challenged with 10 ⁇ l of 0.2% oxazolone on the inner surface of the right ear (day 8).
  • the unchallenged left ears serve as normal controls and dermatitis is evaluated from the difference in pinnal weight which is taken as a measure of inflammatory swelling (day 9).
  • activity of myeloperoxidase (MPO) serving as a measure of leukocyte influx in ear homogenates are determined as described by Bradley et al., J.lnvest.Dermatol; 78:206-209 (1982).
  • mice are treated orally 2 hours after challenge with the test compound of example 10. Activity is calculated as the percentage of inhibition of inflammatory auricular swelling and of MPO activity relative to animals treated with the vehicle alone. For comparison mice are treated intraperitoneally with 100 ⁇ l monoclonal anti-mouse LFA-1 antibody 1 hour before challenge and evaluated as described. b) Results
  • Oral treatment with a single dose of 0.01-10.0 mg/kg of a compound of example 10 results in an inhibition of the inflammatory response by 40-50%. Inhibition of swelling compared with inhibition of MPO activity is observed. Treatment with 50-200 ⁇ g/mouse anti-LFA-1 antibody results in an inhibition by 34-56%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Pharmaceutically active diazepanes, e.g. useful for treating disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions.

Description

DIAZEPANES DERIVATIVES USEFUL AS LFA INHIBITORS
The present invention relates to pharmaceutically active diazepanes.
In one aspect the present invention provides a compound of formula
Figure imgf000002_0001
e.g. including a compound of formula
Figure imgf000002_0002
wherein
R-i is (C )alkyl, e.g. methyl
R2 is unsubstituted (C1_ )alkyl, e.g. methyl, or (d^)alkyl substituted by unsubstituted or substituted
- (C6.i8)aryl, e.g. phenyl or
- (C6.i8)aryl, e.g. phenyl, annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. which aryl or aryl annelated with heterocyclyl is one or morefold substituted by
- halogen,
- halo(C1.6)alkyl,
- (Ct-ejalkoxy,
- cyano,
- amino,
R3 is (C6. 8)aryl, e.g. phenyl, one or morefold substituted by
- halogen, - halotC^alkyl,
- halo(C1-6)alkoxy,
- cyano,
- phenyl,
- heterocyclyl having 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. aromatic heterocyclyl, such as pyrimidinyl.
Preferably in a compound of formula I
- Ri is methyl,
- R2 is methyl or methyl substituted by
- quinolinyl,
- benzo[1 ,3]dioxolyl,
- phenyl
- phenyl one or morefold substituted by halogen,
Figure imgf000003_0001
cyano, amino, dimethylamino, carboxyCC^alkylcarbonylamino, amino(C1.2)alkylcarbonylamino, (C2^)alkylenecarbonylamino, heterocyclylcarbony C^alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, O, such as piperazinyl, morpholinyl,
- R3 is phenyl one or morefold, e.g. 1- to 3-fold, substituted by
- halogen,
- halo(C1.2)alkyl, e.g. CF3;
- halo(C1.2)alkoxy, e.g. OCF3; - cyano,
- phenyl,
- heterocyclyl, including aromatic, having 6 ring members and 2 nitrogen heteroatoms, such as pyrimidinyl.
In another aspect the present invention provides a compound of formula I wherein
- R is methyl,
- R2 is methyl substitued by quinolin-6-yl,
- R3 is phenyl one or morefold, e.g. 1- or 2-fold, substituted by
- halogen, e.g. fluoro, chloro, bromo;
- haloCCt^alkyl, e.g. CF3, - haloCC^alkoxy, e.g. OCF3,
- phenyl,
- aromatic heterocyclyl having 6 ring members and 2 nitrogen heteroatoms, e.g. pyrimidin-5-yl.
In another aspect the present invention provides a compound of formula I wherein
- Ri is methyl,
- R2 is methyl substituted by benzo[1,3]dioxol-5-yl,
- R3 is phenyl one or morefold, e.g. 1- or 2-fold, substituted by
- halogen, e.g. fluoro or chloro;
- halo(Cι_2)alkyl, e.g. CF3;
- halo^.^alkoxy, e.g. OCF3;
- cyano.
In another aspect the present invention provides a compound of formula I wherein
- Ri is methyl,
- R2 is methyl substituted by phenyl or methyl substituted by phenyl one or morefold, e.g. 1 to 3-fold, substituted by
- halogen, e.g. chloro;
- halo(C .2)alkyl, e.g. CF3;
- (C^alkoxy, e.g. methoxy; - cyano,
- amino,
- dimethylamino, - carboxy(C1.2)alkylcarbonylamino,
Figure imgf000004_0001
- ethenylcarbonyl amino
- heterocyclylcarbonyHCt^alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, O, S, preferably from N or O, e.g. piperazin-1-yl or morpholin-4-yl,
- R3 is phenyl substituted one or morefold by
- halogen, e.g. chloro or fluoro;
- halo(C1.2)alkyl, e.g. CF3;
- halo(C1.2)alkoxy, e.g. OCF3; - cyano.
In another aspect the present invention provides a compound of formula I wherein
- Rt is methyl,
- R2 is methyl,
- R3 is phenyl substituted by halogen, e.g. chloro.
In another aspect the present invention provides a compound selected from the group consisting of
- 2-[3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[3,5-cis-3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4- (quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide,
- 2-[5-Methyl-2-oxo-4-(quinolin-6-yl-acetyl)-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[3,5-cis-5- ethyl-2-oxo-4-(quinolin-6-yl-acetyl)-3- (3-trifluoromethyl-phenyl)-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide,
- 2-[3-(4-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[3,5-cis-3-(4-Fluoro-phenyl)-5-methyl-2-oxo-4- (quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide,
- 2-[3-(2-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[3,5-cis-3-(2-Fluoro-phenyl)-5-methyl-2-oxo-4- (quinolin-6-yl-acetyl)-[1 ,4]diazepan-1-yl-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Bromo-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3- naphthalen-1 -yl-propionamide, e.g. 2-[3,5-cis-3-(3-Bromo-phenyl)-5-methyl-2-oxo-4-(2- quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl-3-naphthalen-1 -yl-propionamide,
- 2-[3-Biphenyl-3-yl-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3- naphthalen-1 -yl-propionamide,
- 2-[3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-5-methyl-2-oxo-4- (2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide,
- 2-[3-(3,5-Dichloro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3,5-Dichloro-phenyl)-5-methyl-2-oxo- 4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide,
- 2-[3-(4-Chloro-3-trifluoromethyl-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)- [1 ,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(4-Chloro-3- trifluoromethyl-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1 -yl-propionamide,
2-[3-(3-Chloro-4-fluoro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1- yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Chloro-4-fluoro-phenyl)-5- methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)- [1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide, 2-[5-Methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-3-(2-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]- 3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-5-Methyl-2-oxo-4-(2-quinolin-6-yl- acetyl)-3-(2-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide, 2-[3-(3,4-Difluoro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3,4-Difluoro-phenyl)-5-methyl-2-oxo- 4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide, • 2-[3-(3-Cyano-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Cyano-phenyl)-5-methyl-2-oxo-4- (2-quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide, ■ 2-[5-Methyl-2-oxo-3-(3-pyrimidin-5-yl-phenyl)-4-(2-quinolin-6-yl-acetyl)-[1 ,4]diazepan-1-yl]- 3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[5-Methyl-2-oxo-3-(3-pyrimidin-5-yl-phenyl)-4- (2-quinolin-6-yl-acetyl)-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide, ■ 2-[5-Methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-3-(3-trifluoromethoxy-phenyl)-[1,4]diazepan-1- yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-5-Methyl-2-oxo-4-(2-quinolin-6-yl- acetyl)-3-(3-trifluoromethoxy-phenyl)-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide,
■ 2-[4-(2-Benzo[1 ,3]dioxol-5-yl-acetyl)-3-(3-fluoro-phenyI)-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]- 3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[4-(2-Benzo[ 1 ,3]dioxol-5-yl-acetyl)-3,5-cis-3-(3- fluoro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide,
■ 2-[4-(2-Benzo[1 ,3]dioxol-5-yl-acetyl)-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1- yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2-Benzo[1 ,3]dioxol-5-yl-acetyl)- 3-(3-chloro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide,
• 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)- [1 ,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2- Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1- yl]-3-naphthalen-1-yl-propionamide,
■ 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-chloro-4-fluoro-phenyl)-5-methyl-2-oxo- [1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2-
Benzo[1 ,3]dioxol-5-yl-acetyl)-3-(3-chloro-4-fluoro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1 - yl]-3-naphthalen-1-yl-propionamide,
■ 2-[4-(2-Benzo[1 ,3]dioxol-5-yl-acetyl)-3-(3-cyano-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]- 3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2-Benzo[1 ,3]dioxol-5-yl-acetyl)-3- (3-cyano-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide,
■ 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethoxy-phenyl)- [1 ,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2- Benzo[1 ,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethoxy-phenyl)-[1 ,4]diazepan-1 - yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-phenylacetyl-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 - yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-phenylacetyl- [1 ,4]diazepan-1 -yI]-3-naphthalen-1 -yl-propionamide,
- 2-[3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4-[(3-trifluoromethyl-phenyl)-acetyl]-[1,4]diazepan-1- yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-{3,5-cis-3-(3-Fluoro-phenyl)-5-methyl-2-oxo- 4-[(3-trifluoromethyl-phenyl)-acetyl]-[1 ,4]diazepan-1 -yl}-3-naphthalen-1 -yl-propionamide,
- 2-{3-Biphenyl-4-yl-5-methyl-2-oxo-4-[2-(2,3,6-trichloro-phenyl)-acetyl]-[1 ,4]diazepan-1-yl}-3- naphthalen-1 -yl-propionamide, e.g. 3,5-cis-2-{3-Biphenyl-4-yl-5-methyl-2-oxo-4-[2-(2,3,6- trichloro-phenyl)-acetyl]-[1 ,4]diazepan-1 -yl}-3-naphthalen-1 -yl-propionamide,
- 2-[4-[2-(4-Cyano-phenyl)-acetyl]-3-(3,4-difluoro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1 - yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-[2-(4-Cyano-phenyl)-acetyl]-3- (3,4-difluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide,
- 2-[3-(3-Chloro-phenyl)-4-[2-(4-cyano-phenyl)-acetyl]-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-4-[2-(4-cyano- phenyl)-acetyl]-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide,
- 2-[4-[2-(4-Amino-phenyl)-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-[2-(4-Amino-phenyl)-acetyl]-3-(3- chloro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide,
- 2-[4-[2-(4-Amino-phenyl)-acetyl]-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan- 1-yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-[2-(4-Amino-phenyl)-acetyl]-5- methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1 -yl- propionamide,
- 2-[4-[2-(4-Dimethylamino-phenyl)-acetyl]-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)- [1 ,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-[2-(4-
Dimethylamino-phenyl)-acetyl]-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1- yl]-3-naphthalen-1-yl-propionamide,
2-[4-[2-(3-Amino-phenyl)-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3- naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-[2-(3-Amino-phenyl)-acetyl]-3-(3- chloro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl]-3-naphthalen-1 -yl-propionamide,
N-(4-{2-[4-(1 -Carbamoyl-2-naphthalen-1 -yl-ethyl)-7-methyl-3-oxo-2-(3-trifluoromethyl- phenyl)-[1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid, e.g. N-(4-{2-[(2S,7R)-4-
((R)-1-Carbamoyl-2-naphthalen-1-yl-ethyl)-7-methyl-3-oxo-2-(3-trifluoromethyl-phenyl)-
[1 ,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid,
- N-(4-{2-[4-(1 -Carbamoyl-2-naphthalen-1 -yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-
[1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid, e.g. N-(4-{2-[(2S,7R)-4-((R)-1-
Carbamoyl-2-naphthalen-1 -yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1 ,4]diazepan-1 -yl]-
2-oxo-ethyl}-phenyl)-succinamic acid,
• N-(3-{2-[4-(1 -Carbamoyl-2-naphthaien-1 -yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid, e.g. N-(3-{2-[(2S,7R)-4-((R)-1- Carbamoyl-2-naphthalen-1 -yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1 ,4]diazepan-1 -yl]- 2-oxo-ethyl}-phenyl)-succinamic acid,
■ 2-[4-{2-[4-(2-Amino-acetylamino)-phenyl3-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo- [1 ,4]diazepan-1-yI]-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-{2-[4-(2-Amino- acetylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3- naphthalen-1 -yl-propionamide,
• 2-[4-{2-[3-(2-Amino-acetylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo- [1 ,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-{2-[3-(2-Amino- acetylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3- naphthalen-1 -yl-propionamide,
• 2-[4-{2-[4-(3-Amino-propionylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo- [1 ,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-{2-[4-(3-Amino- propionylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3- naphthalen-1 -yl-propionamide,
■ N-(4-{2-[4-(1 -Carbamoyl-2-naphthalen-1 -yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1 ,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-acrylamide, e.g. N-(4-{2-[4-((R)-1-Carbamoyl-2- naphthalen-1 -yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1 ,4]diazepan-1 -yl]-2-oxo-ethyl}- phenyl)-acrylamide, - N-(4-{2-[4-(1 -Carbamoyl-2-naphthalen-1 -yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-
[1 ,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-4-morpholin-4-yI-4-oxo-butyramide, e.g. N-(4-{2- [(2S,7R)-4-((R)-1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-4-morpholin-4-yl-4-oxo-butyramide, - N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1 ,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-4-oxo-4-piperazin-1-yl-butyramide, e.g. N-(4-{2- [(2S,7R)-4-((R)-1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chIoro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-4-oxo-4-piperazin-1-yl-butyramide,
- 2-{3-(3-Chloro-phenyl)-4-[2-(2-methoxy-phenyl)-acetyl]-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl}- 3-naphthalen-1 -yl-propionamide, e.g. (R)-2-{(3S,5R)-3-(3-Chloro-phenyl)-4-[2-(2-methoxy- phenyl)-acetyl]-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl}-3-naphthalen-1 -yl-propionamide,
- 2-{3-(3-Chloro-phenyl)-4-[2-(4-methoxy-phenyl)-acetyl]-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl}- 3-naphthalen-1 -yl-propionamide, e.g. (R)-2-{(3S,5R)-3-(3-Chloro-phenyl)-4-[2-(4-methoxy- phenyl)-acetyl]-5-methyl-2-oxo-[1 ,4]diazepan-1 -yl}-3-naphthalen-1 -yl-propionamide,
- 2-[4-[2-(3-Chloro-4-methoxy-phenyl)-acetyl]-(3-(3-chloro-phenyl)-5-methyl-2-oxo- [1 ,4]diazepan-1-yl]-3-naphthalen-1 -yl-propionamide, e.g. (R)-2-[(3S,5R)-4-[2-(3-Chloro-4- methoxy-phenyl)-acetyl]-(3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3- naphthalen-1 -yl-propionamide,
- 2-[4-Acetyl-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepam-1 -yl]-3-naphthalen-1 -yl propionamide, e.g. (R)-2-[(3S,5R)-4-Acetyl-3-(3-chloro-phenyl)-5-methyl-2-oxo-
[1 ,4]diazepam-1-yl]-3-naphthaIen-1-yl propionamide,
In another aspect the present invention provides a compound of formula I which is a compound of formula
Figure imgf000009_0001
e.g. including the compound
Figure imgf000010_0001
In another aspect the present invention provides (R)-2[(3S,5R)-4-(2-Benzo[1 ,3]dioxol-5-yl- acetyl)-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepam-1 -yl]-3-naphthalen-1 -yl- propionamide.
If not otherwise defined herein
- alkyl includes linear or branched (Cι^)alkyl, such as (CM)alkyl, e.g. (C^alkyl, including unsubstituted or substituted alkyl, e.g. alkyl substituted by groups which are conventional in organic chemistry, e.g. halogen, OH, NH2 or haloCd-eJalkyl,
- haloalkyl includes halo(Cι.6)alkyl, such as haloCC^alkyl, e.g. halo(Cι_2)alkyl, wherein one or more halogen(s) is (are) present in the alkyl group, preferably -CF3,
- halogen includes fluoro, chloro, bromo, iodo, e.g. fluoro, chloro, bromo, preferably fluoro or chloro,
- amino includes unsubstituted and substituted amino, e.g. amino substituted by (Ct-^alkylamino, d C^alkylamino and amino substituted by acyl,
- acyl includes acyl, having 1 to 12 carbon atoms altogether, e.g.
Figure imgf000010_0002
such as carboxy(Cι_3)alkylcarbonyl, aminoCC^alkylcarbonyl, such as amino- (Cι-3)alkylcarbonyl, (C^alkenylcarbonyl or heterocyclylcarbony C^alkylcarbonyl, wherein heterocyclyl has 5 or 6 ring members and 1 to 4 heteroatoms, preferably 1 or 2 heteroatoms, selected from N, O, S, preferably N, O, e.g. piperazinyl or morpholinyl,
- heterocyclyl includes heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, preferably N, O, such as alicyclic and aromatic heterocyclyl, e.g. heterocyclyl having 6 ring members and 1 to 2 heteroatoms selected from N, O, e.g. piperazinyl, morpholinyl, pyrimidinyl,
- aryl includes (C6-ι8)aryl, e.g. phenyl, and (C6.i8)aryl, e.g. phenyl, annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, preferably N, O, e.g. heterocyclyl having 5 ring members and 2 heteroatoms selected from N, O, preferably benzo(1 ,3)dioxol-4-yl, benzo(1,3)dioxol-5-yl,quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl.
Compounds provided by the present invention, e.g. including compounds of formula I, lA, IPREF and ΓPREF are hereinafter designated as "compound(s) of (according to) the present invention". Each single substituent defined above in a compound of the present invention may be per se a preferred substituent, independently of the other substituents defined.
A compound of the present invention includes a compound in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a salt and in the form of a solvate. A compound of the present invention in free form may be converted into a corresponding compound in the form of a salt; and vice versa. A compound of the present invention in free form or in the form of a salt and in the form of a solvate may be converted into a corresponding compound in free form or in the form of a salt in unsolvated form; and vice versa.
In another aspect the present invention provides a compound of the present invention in the form of a salt.
A salt of a compound of the present invention includes a pharmaceutically acceptable salt, e.g. including a metal salt or an acid addition salt. Metal salts include for example alkali or earth alkali; acid addition salts include salts of a compound of formula I with an acid, e.g. acetic acid, trifluoroacetic acid, hydrochloric acid.
A compound of the present invention may exist in the form of isomers and mixtures thereof; e.g. optical isomers, diastereoisomers, cis/trans isomers. A compound of the present invention may e.g. contain asymmetric carbon atoms and may thus exist in the form of diastereoisomeres and mixtures thereof or enantiomers or mixtures thereof, e.g. racemates. For example the groups R^ R3 and the group naphthylmethyl in position * in a compound of formula I may be in the (R)- or in the (S)-configuration, e.g. including mixtures therof. Preferably the naphthylmethyl group and Rt in a compound of formula I both are in the (R)- configuration and R3 is in the (S)-configuration. Isomeric mixtures may be separated as appropriate, e.g. according, such as analogously, to a method as conventional, to obtain pure isomers. The present invention includes a compound of the present invention in any isomeric form and in any isomeric mixture.
Similar considerations apply in relation to starting materials exhibiting isomeric features, e.g. analogously as indicated above.
Any compound described herein, e.g. a compound of the present invention, may be prepared as appropriate, e.g. according, e.g. analogously, to a method as conventional, e.g. or as specified herein. Starting materials are known or may be prepared according, e.g. analogously, to a method as conventional or as described herein.
In another aspect the present invention provides a process for the preparation of a compound of the present invention comprising A) reacting a compound of formula
Figure imgf000012_0001
wherein R^ and R3 are as defined above, with a compound of formula
Figure imgf000012_0002
e.g. in a protected form, e.g. in the presence of a
- condensing agent, e.g. a carbodiimide
- a base, e.g. an amine, such as diidopropylethylamine or dimethylaminopyridine, in organic solvent, e.g. polar organic solvent, such as N,N-dimethylformamide, optionally deprotecting, and optionally further reacting, to obtain a compound of formula I and isolating a compound of formula I,
OR
B) reacting a compound of formula
Figure imgf000013_0001
wherein R^ and R2 are as defined above, with an optionally substituted compound of formula
Figure imgf000013_0002
wherein A denotes an aromatic heterocyclyl having 5 (n=1) or 6 (n=2) ring members and 1 to
4 heteroatoms selected from N, O, S, e.g. in the presence of a catalyst, e.g. Pd(PPh3)4, to obtain a compound of formula I wherein R3 is phenyl substituted by optionally substituted phenyl or aromatic heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, and isolating a compound of formula I obtained from the reaction mixture.
An optionally protected group R2 of formula III e.g. includes phenyl substituted by an amine. Such amine may be protected by an appropriate protection group, e.g. including tert- butoxycarbonyl (Boc), which protecting group may be removed after reaction of a compound of formula II with a compound of formula III to obtain a free amine group. Further reacting e.g. includes alkylating or acylating such amine group as appropriate, e.g. according, e.g. analogously, to a method as conventional.
In an intermediate of formula II or of formula IV (starting materials), functional groups, if present, optionally may be in protected form or in the form of a salt, if a salt-forming group is present. Protecting groups, optionally present, may be removed at an appropriate stage, e.g. according, e.g. analogously, to a method as conventional A compound of formula I thus obtained may be converted into another compound of formula I, e.g. or a compound of formula I obtained in free form may be converted into a salt of a compound of formula I and vice versa.
In another aspect the present invention provides
- a compound of formula II wherein Ri and R3 are as defined above, and
- a compound of formula IV, wherein Ri and R2 are defined as above, e.g. useful as intermediates for the production of a compound of the present invention.
The above reaction A) is a an amine acylation reaction and may be carried out as appropriate, e.g. according, e.g. analogously, to a method as conventional or as described herein. The above reaction B) is a cross coupling reaction and may be carried out as appropriate, e.g. according, e.g. analogously, to a method as conventional or as described herein.
Any compound described herein, e.g. a compound of the present invention and intermediates of formula II and IV, may be prepared as appropriate, e.g. according, e.g. analogously, to a method as conventional, e.g. or as specified herein.
The compounds of the present invention exhibit valuable pharmacological properties, e.g. by mediating, such as inhibiting, the activity of LFA-1/ICAM-1 , LFA-1 /ICAM-2, LFA- /ICAM-3 or LFA-1/JAM-1 interactions and thus mediating, e.g. inhibiting inflammation, e.g. as indicated in in vitro and in vivo TEST SYSTEMS herein and are therefore indicated for therapy.
A. In vitro TEST SYSTEM: (Cell free assay)
The assay determines the binding of soluble human ICAM-1 to immobilized human LFA-1.
LFA-1 is purified from JY cells, a human lymphoblastoid B cell-line, by immunoaffinity chromatography analogously as described by Dustin et al., J. Immunol. 148, 2654-2663,
1992. ICAM-1 mouse CK fusion protein (ICAM-1) is produced using the baculovirus system as described by Weitz-Schmidt et al., Anal. Biochem. 238,184-190, 1996.
Purified LFA-1 is diluted 1 :20 in phosphate buffered saline (PBS) containing 2 mM MgCI2, pH
7.4 and coated onto microtiter plates (Nunc) at 37° for 3 hours. Plates are blocked with 1% heat-treated bovine serum albumin in PBS for 2 hours at 37° followed by a washing step using PBS, 2 mM MgCI2) 1% fetal calf serum, pH 7.4 (assay buffer). Compounds of the present invention (10 mM solution in DMSO) are diluted in assay buffer and added to the plates. Biotinylated recombinant ICAM-1 in assay buffer (6 μg/ml) is added and allowed to bind at 37° for one hour. After incubation, wells are washed with assay buffer. Streptavidin- peroxidase diluted 1:5000 in assay buffer is added and incubated for 45 min at 37°. Plates are washed with assay buffer and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt substrate solution is added to each well. The reaction is stopped after 20 minutes and bound ICAM-1 is determined by measuring the optical density at 405 nm in a microplate reader.
In this assay the compounds of the present invention exhibit activity, e.g. the compounds of the present invention inhibit adhesion of LFA-1 to ICAM-1 with an IC50 < 50 μM, preferably 0.05 to 50 μM. The compounds of examples 13 and 14 are preferred compounds of the present invention and show IC50 values of 0.43 or 0.09 μM, respectively, in this assay. We have surprisingly found that compounds of formula I, wherein R3 is substituted phenyl show higher IC50 values in such LFA-1 in vitro TEST SYSTEM than compounds of formula I, wherein R3 is unsubstituted phenyl.
B. In vivo TEST SYSTEM: Allergic Contact Dermatitis (ACD)
Groups of 8 female NMRI mice are sensitized on the shaved abdomen with 50 μl of oxazolone (2% in acetone) and challenged with 10 μl of 0.2% oxazolone on the inner surface of the right ear 7 days later. The unchallenged left ears serve as normal controls and dermatitis is evaluated from the individual differences in auricular weights, which are taken as a measure of inflammatory swelling 24 hours after the challenge. Dermatitis is evaluated in test- and control groups. The test groups are treated with the test compounds orally (2 hours after challenge), the controls are treated similarly with the vehicles alone. For oral administration the compounds are administered in an oil in H2O emulsion. The data of the test- and the vehicle-treated control groups are statistically analysed by ANOVA followed by Dunnet T-test (normal distribution or data) or by H and U-test, respectively. When administered p.o. at a dose of from 0.03 to 30 mg/kg, the compounds of the present invention inhibit the elicitation phase of allergic contact dermatitis. For example, compound of Example 14 has an inhibiting effect in this assay of >30% when administered p.o. at a dose of 0.03 mg/kg.
The compounds of the present invention are therefore expected to be useful in the treatment of diseases or disorders mediated by interactions of LFA-1 with its ligands involved in cell adhesion, migration and activation. The compounds may be preferably useful for treatment of inflammatory conditions, allergic diseases or autoimmune diseases. Examples are inflammatory injuries of the skin (psoriasis, eczemas, urticaria, acne, pyoderma gangrenosum, sun burns or toxic epidermal necrolysis), lung (adult respiratory distress syndrome, COPD), kidney (acute/chronic interstitial/glomerulonephritis), liver (acute/chronic hepatitis, granulomatous diseases), cardiovascular system (ischemia/reperfusion injuries, shock, arteriosclerosis, vasculitides), eye (conjunctivitis, keratitis) or gastrointestinal tract (Crohn's disease, ulcerative colitis). Examples of allergic conditions are allergic contact dermatitis, atopic dermatitis or asthma. Rheumatoid arthritis, multiple sclerosis, (systemic) lupus erythematosus, Sjogren" syndrome, alopecia areata, uveitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa or myasthenia gravis are examples of auto-immune mediated conditions.
The compound of the present invention may also be used for prevention of acute and chronic rejection of allo- or xenografts, transplantation, host vs. graft or graft vs. host diseases, for the treatment of neoplastic diseases including metastasis of neoplastic or cancerous growth or cancer, AIDS and infectious diseases. Treatment includes prophylaxis.
The compound of the present invention may be preferably useful for treatment of psoriasis, rheumatoid arthritis, inflammatory bowel diseases (Crohn s disease, ulcerative colitis), (systemic) lupus erythematosus, atopic dermatitris, Sjogren' syndrom, rejection after transplantation and graft vs. host disease.
In one preferred aspect the compounds of the present invention are useful in the treatment of autoimmune diseases, e.g. rheumatoid arthritis, or of inflammatory diseases, e.g. psoriasis or atopic dermatitis, such as rheumatoid arthritis.
For the above uses the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, satisfactory results are indicated to be obtained systemically at daily dosages of a compound of the present invention from about 0.1 mg/kg to about 100 mg/kg body weight. An indicated daily dosage in the larger mammals, e.g. humans, is in the range from about 0.5 mg to about 500 mg (e.g. about 0,00625 mg/kg to about 6,25 mg/kg), conveniently administered, for example, in divided doses up to four times a day or in retard form. The compounds of the present invention may be administered systemically or topically, by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Percutaneous administration via patches or other delivery systems may also be a possible route for prophylaxis or treatment of above diseases.
For topical use, e.g. including administration to the eye, satisfactory results may be obtained with local administration of a 0.5-10 %, such as 1-3% concentration of active substance several times daily, e.g. 2 to 5 times daily.
In another aspect the present invention provides a compound of the present invention for use as a pharmaceutical, e.g. against diseases as indicated above, such as rheumatoid arthritis.
For pharmaceutical use a compound of the present invention includes one or more, preferably one, compounds of the present invention, e.g. a combination of two or more compounds of the present invention.
In another aspect the present invention provides the use of a compound of the present invention for the manufacture of a medicament, e.g. a pharmaceutical composition, for the treatment of a disease as indicated above, for example of diseases mediated by LFA- l/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions, e.g against inflammatory diseases, allergic conditions or autoimmune diseases, such as autoimmune diseases, e.g. psoriasis, asthma or rheumatoid arthritis.
In another aspect the present invention provides a pharmaceutical composition comprising a compound of the present invention in association with at least one pharmaceutically acceptable excipient, e.g. including a carrier and/or diluent, e.g. including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers.
Such compositions may be manufactured according, e.g. analogously, to a method as conventional, e.g. by mixing a compound of the present invention with a pharmaceutically acceptable excipient, e.g. a carrier and/or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 1000 mg (e.g. from about 0.00125 mg/kg to about 12.5 mg/kg), e.g. 0.5 mg to 500 mg, such as e.g. 1 mg to about 125 mg of a compound of the present invention.
The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt, e.g. an acid addition salt or metal salt; or in free form; optionally in the form of a solvate. The compounds of the present invention in the form of a salt exhibit the same order of activity as the compounds of the present invention in free form; optionally in the form of a solvate.
In another aspect the present invention provides:
- A method for treatment of disorders or diseases mediated by LFA-1 /ICAM-1 , LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions, e.g. such as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of the present invention; and
- A method for treatment of diseases as indicated above, e.g. inflammatory, allergic or autoimmune diseases, e.g. as indicated above, e.g. psoriasis, asthma, rheumatoid arthritis, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of the present invention.
For such treatment, the appropriate dosage will, of course, vary depending upon, for example, the chemical nature and the pharmakokinetic data of a compound of the present invention employed, the individual host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.01 g to about 1.0 g (e.g. from about 0,125 mg/kg to about 12,5 mg/kg), of a compound of the present invention; conveniently administered, for example, in divided doses up to four times a day.
A compound of the present invention may be administered by any conventional route, for example enterally, e.g. including nasal, buccal, rectal, oral, administration; parenterally, e.g. including intravenous, intramuscular, subcutanous administration; or topically; e.g. including epicutaneous, intranasal, intratracheal administration; e.g. in form of coated or uncoated tablets, capsules, injectable solutions or suspensions, e.g. in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops, sprays, or in the form of suppositories.
A compound of the present invention may be used for pharmaceutical treatment according to the present invention alone or in combination with at least one, e.g. one or more, other pharmaceutically active agents. Such other pharmaceutically active agents e.g. include compounds active in immunomodulating regimens or other anti-inflammatory agents, e.g. for the treatment or prevention of inflammatory or allergic conditions, autoimmune disorders, or acute or chronic rejection of allo- or xenograft. For example, compounds of the present invention may be used in combination with cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g. cyclosporin A, cyclosporin G, FK-506, ASM 981 , rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin etc., corticosteroids, cyclophosphamide, azathioprene, methotrexate, FTY 720, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxyspergualine, immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45, or CD58 or their ligands, or other immunomodulatory compounds, e.g. CTLA4lg, or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including selectin antagonists and VLA-4 antagonists.
Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation; kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e.g. with instructions for co- administration; and free combinations in which the pharmaceutically active agents are packaged separately, but instructions for simultaneous or sequential administration are given.
If the compounds of the present invention are administered in combination with other immunosuppressive/immunomodulatory or anti-inflammatory active agents, e.g.for preventing or treating acute or chronic rejection or inflammatory or autoimmune disorders as hereinabove specified, dosages of the co-administered immunosuppressant, immunomodulatory or anti-inflammatory compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a cyclosporin, on the specific drug employed, on the condition being treated and so forth. In general comparable dosage ranges as indicated for the co-administration may be are appropriate. In another aspect the present invention provides a pharmaceutical composition according to the present invention, further comprising another pharmaceutically active agent.
In another aspect the present invention provides
- A method for treatment of disorders or diseases as indicated above comprising co-administrating, e.g. concomitantly or in sequence, a therapeutically effective amount of at least one compound of the present invention and at least one second pharmaceutically active agent, said pharmaceutically active agent being selected from the group consisting of immunosuppressants, immunomodulatory or anti-inflammatory active agents, e.g. such as indicated above; and
- A pharmaceutical combination, e.g. a kit, for use in a method for treatment according to the present invention, comprising at least one compound of the present invention to be used concomitantly or in sequence with at least one immunosuppressant, immunomodulatory or anti-inflammatory active agent. The kit may comprise instructions for concomitant administration or administration in sequence.
In another aspect the present invention provides a compound of formula
Figure imgf000020_0001
wherein
R1P is (C- jalkyl,
R2p is (C^alkyl or -(CH2)n-R p, wherein n is 1 , 2, 3 or 4 and
R4P is unsubstituted or substituted
- phenyl or
- phenyl annelated with another ring system, which other ring system is a 5- or 6-membered heterocycle, having one to 4 heteroatoms selected from N, O, S, e.g. wherein substituents are selected from the group consisting of
- halogen,
- unsubstituted amino or amino substituted by one or two (CM)alkyl, - cyano,
- (C^alkoxy,
- (C^haloalkyl and
R3P is substituted phenyl, e.g. one or morefold, wherein the substituents are selected from the group consisting of
- halogen,
- (Ct-ejhaloalkyl,
- unsubstituted or substituted phenyl, wherein substitutents are as indicated under "substituted phenyls" in the meaning of R4P, e.g. in the form of a salt and/or solvate.
In the following examples all temperatures are in degree (°) Celsius. In the reaction schemes and corresponding description R2 and R3 are as defined above.
The following ABBREVIATIONS are used:
AcOH acetic acid Boc tert.-butoxy-carbonyl
DBU 1,4-diaza-bicyclo[5.4.0]undec-7-en DIEA diisopropylethylamine
DIPCI diisopropylcarbodiimide DMAP N,N-dimethyl-4-aminopyridine
DMF N,N-dimethylformamide EtAc ethyl acetate equiv. equivalent EX example
HOAt 1-hydroxy-7-azabenzotriazole i-PrOH isopropanol
MeOH methanol NMM N-methyl-morpholine rt room temperature THF tetrahydrofurane
TFA trifluoroacetic acid TsOH p-toluenesulfonic acid
Z benzyloxycarbonyl
EDC N-ethyl-N,-(3-dimethylaminopropyl)-carbodiimide
EDC-HCI N-ethyl-Nx-(3-dimethylaminopropyl)-carbodiimide in the form of a hydrochloride
EXAMPLES
PROCEDURE A
Synthesis of compounds of the present invention
Aa. Synthesis of a ketal intermediate
Figure imgf000022_0001
Naphthylalanine amide of formula A1 and 0.3 equiv. of NMM are dissolved in dioxane and 1.5 equiv. of methylvinylketone are added. The mixture obtained is stirred at RT for 15 hours and 5 equiv. of 2-methoxydioxolane and 1.5 equiv. of TsOH-monohydrate are added. The mixture obtained is stirred and diluted with EtAc. The organic phase obtained is washed and dried, solvent is evaporated and a ketal intermediate of formula A2 is obtained, which is optionally purified or used without further purification. Ab. Amine-protection of phenylqlvcines
Figure imgf000022_0002
A compound of formula Phe-gly, wherein R3 is as defined above, is dissolved in MeOH. 2 equiv. of NaHCO3and 1.2 equiv. of Boc-anhydride are added to the solution obtained and the suspension obtained is heated at 50° under stirring. From the mixture obtained solvent is evaporated and H2O and toluene are added. The phases obtained are separated and the organic phase obtained is extracted with 1N NaOH. The pH of the aqueous phase obtained is adjusted to pH 3 and the mixture obtained is extracted with EtAc. The organic phase obtained is dried, solvent is evaporated and racemic Boc-phenylglycine of formula A3, wherein R3 is as defined above, is obtained. Ac. Amine acylation
Compound of formula A2 A4
Figure imgf000023_0001
1 equiv. of a compound of formula A2, wherein R3 is as defined above, 1.5 equiv. of racemic (substituted) Boc-phenylglycine of formula A3, wherein R3 has the meaning as indicated above, and 0.12 equiv. of HOAt are dissolved in DMF. 1.5 equiv. of DIEA and 1.5 equiv. of EDC in free base form are added during 15 hours at rt. Solvent is evaporated, the evaporation residue obtained is diluted with EtAc and extracted with 1 N HCI and 5% NaHCO3 solution. The organic phase obtained is dried and solvent is evaporated. A compound of formula A4, wherein R3 is as defined above, is obtained in the form of a diastereoisomeric mixture. Ab. Deprotection and reductive ring closure
Compound of formula A4
Figure imgf000023_0002
A compound of formula A4, wherein R3 is as defined above, is dissolved in TFA/H2O at 0°. The mixture obtained is stirred, quenched with H2O and solvent is evaporated. A diastereoisomeric mixture of a compound of formula A4, wherein the Boc-NH- group is deprotected is obtained and is dissolved in MeOH/H2O. The pH of the mixture obtained is adjusted to pH 5. 0.5 equiv. of a NaCNBH3-solution in MeOH/H2O are added at 0° to the mixture obtained, the mixture obtained is stirred, solvent is evaporated and the evaporation residue obtained is diluted with EtAc.3.5M phosphate-buffer of pH 4 are added to the mixture obtained, two phases are obtained and are separated. The organic phase obtained is extracted with 5% NaHCO3 solution, dried and solvent is evaporated. A compound of formula A5, wherein R3 is as defined above, is obtained. Ae. Acylation of diazepanes
Compound of formula A5
Figure imgf000024_0001
A compound of formula A5, wherein j is as defined above, is treated with 1.7 equiv. of R COOH, wherein R2 is as defined above, 1.3 equiv. of DIEA and 0.2 equiv. of HOAt in DMF. The mixture obtained is heated to 35° and 1.7 equiv. of EDC are added and the mixture obtained is stirred for 15 hours at 35°. From the mixture obtained solvent is evaporated, the evaporation residue obtained is dissolved in EtAc and extracted with 1N HCI and 5% NaHCO3 solution. The organic phase obtained is dried and solvent is evaporated. A compound of formula A6 is obtained, which is optionally subjected to chromatography (e.g. silica gel, toluene/i-PrOH), in order for further purification, if desired. PROCEDURE B
The compound of example 22 is treated with 1.5 equiv. of N-Boc-beta-alanine, or N-Boc- glycine, respectively, 1.5 equiv. of EDC-HCI and 0.5 equiv. of DMAP in DMF at rt. The mixture obtained is diluted with EtAc and 1 N HCI, two phases are obtained and are separated, the organic phase obtained is washed, dried and solvent is evaporated. The evaporation residue obtained is dissolved in TFA/H O at 0°, stirred, diluted with dioxane and solvent is evaporated. A residue obtained is subjected to RP-chromatography. The compounds of example 31 and example 29, respectively, in the form of a trifluoroacetate are obtained. When using the compound of example 25 and N-Boc-glycine, the compound of example 30 is obtained. PROCEDURE C
The compound of example 31 is treated with an excess of CH3J in CH2CI2/K2CO3 at rt. From the mixture obtained solvent is evaporated, the evaporation residue obtained is dissolved in MeOH/H2O and worked up by solid-phase extraction (C-18 cartridge, MeOH/H2O gradient).
The compound of example 32 is obtained.
PROCEDURE D
The compound of example 22, or example 23, respectively, is treated with succinic acid anhydride. Depending on the starting materials, the compound of example 27, or example
27, respectively, is obtained.
PROCEDURE E
The compound of example 27 is treated with 6 equiv. of morpholine and 2 equiv. of EDC-HCI in DMF at 0° for 4 hours at pH 8 (adjustment by addition of TFA). The mixture obtained is diluted with EtAc and 1N HCI, two phases obtained are separated, the organic phase obtained is washed, dried and solvent is evaporated. The compound of example 33 is obtained.
PROCEDURE F
The compound of example 27 is treated with 6 equiv. of piperazine and 2 equiv. of EDC-HCI in DMF at pH=8 (pH-adjustment by addition of TFA). The mixture obtained is diluted with
EtAc and 5M pH 4 phosphate buffer, two phases obtained are separated, the organic phase obtained is washed, dried and solvent is evaporated. The compound of example 34 is obtained.
PROCEDURE G
The compound of example 5 is treated with phenylboronic acid, or pyrimidine-5-boronic acid, respectively, in the presence of a catalytic amount of palladium tetrakistriphenylphosphine in dimethoxyethane/aqeous Na2CO -solution (6:1) at 130° for 10 minutes in a closed vessel.
The mixture obtained is diluted with EtAc, extracted at pH 4 with phosphate buffer and aqueous Na2CO solution, and, from the organic layer obtained, solvent is evaporated.
Depending on the boronic acid used, a compound of example 6, or 12b, respectively, is obtained. A compound of example 6 is treated with trifluoroacetic acid and the compound of example 6 is obtained in the form of a trifluoroacetate.
Analogously to procedures as described above, but using appropriate starting materials, compounds of formula I wherein Rt is methyl and R2 and R3 are as defined in TABLE 1 below are obtained.
The compounds of examples
- 1-5, 7-25, 27-28 and 35-38 are prepared according to procedure A;
- 6 and 12b are prepared according to procedure G; - 26 and 27 are prepared according to procedure D;
- 29-31 are prepared according to procedure B;
- 32 is prepared according to procedure C;
- 33 is prepared according to procedure E;
- 34 is prepared according to procedure F
The compounds of examples 6, 11 , 23, 25, 29 and 31 are obtained in the form of a trifluoroacetate.
Under "DATA" in TABLE 1 there are also indicated
- Rf values (thin layer chromatography on silica gel 60, in toluene/i-PrOH 1:1 (=T) or EtAc
(=E);
- 1H-NMR data in CDCI3, unless otherwise indicated.
TABLE 1
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
PREPARATION OF STARTING MATERIALS Naphythylalanine amide (Compound A1)
Naphthalene-1 -carboxylic acid is dissolved in dry THF and 5 equiv. of borane dimethylsulfide complex are added. The mixture obtained is stirred at rt, diluted with EtAc, washed with 1N HCI and 5% NaHCO3 solution, dried and solvent is evaporated. (Naphthalene-1 -yl)-methanol is obtained, which is dissolved in CH2CI2. To the solution obtained 1.5 equiv. of Dess-Martin reagent are added at rt. The mixture obtained is diluted with EtAc, extracted with 1 N HCI and 5% NaHCO3-solution, dried and solvent is evaporated. Naphthalene-1 -carboxaldehyde is obtained and dissolved with 1 equiv. of racemic-Boc-α-phosphonoglycine trimethylester in CH2CI2 and 1.1 equiv. of DBU are added. The mixture obtained is stirred at rt and treated in sequence with 1 N HCI and 5% NaHCO3 solution. The phases obtained are separated, the organic phase obtained is dried and solvent is evaporated. 2-Boc-amino-3-(naphtha!ene-1- yl)-acrylic acid methyl ester (cis/trans mixture) is obtained, is dissolved in MeOH/H2O at pH 6.5 (phosphate buffer) and 20 w/w% of 10% Pd/C are added. The mixture obtained is hydrogenated at rt and 50 bar, the catalyst is filtered off and from the filtrate obtained solvent is evaporated. Racemic naphythylalanine methylester is obtained, dissolved in methanolic NH3 and stirred. The mixture obtained is subjected to extractive work up. Racemic naphythylalanine amide is obtained.
TEST Example
Inhibition of allergic contact dermatitis (ACD) in vivo a. Method:
Groups of 8 female mice are sensitized epicutaneously with 50 μl of 2% oxazolone on the shaved ventral abdomen (day 1) and challenged with 10 μl of 0.2% oxazolone on the inner surface of the right ear (day 8). The unchallenged left ears serve as normal controls and dermatitis is evaluated from the difference in pinnal weight which is taken as a measure of inflammatory swelling (day 9). In addition, activity of myeloperoxidase (MPO) serving as a measure of leukocyte influx in ear homogenates are determined as described by Bradley et al., J.lnvest.Dermatol; 78:206-209 (1982). The animals are treated orally 2 hours after challenge with the test compound of example 10. Activity is calculated as the percentage of inhibition of inflammatory auricular swelling and of MPO activity relative to animals treated with the vehicle alone. For comparison mice are treated intraperitoneally with 100 μl monoclonal anti-mouse LFA-1 antibody 1 hour before challenge and evaluated as described. b) Results
Oral treatment with a single dose of 0.01-10.0 mg/kg of a compound of example 10 results in an inhibition of the inflammatory response by 40-50%. Inhibition of swelling compared with inhibition of MPO activity is observed. Treatment with 50-200 μg/mouse anti-LFA-1 antibody results in an inhibition by 34-56%.

Claims

Patent claims
1. A compound of formula
Figure imgf000037_0001
wherein
Rt is (C^)alkyl,
R2 is unsubstituted
Figure imgf000037_0002
or (CM)alkyl substituted by unsubstituted or substituted
- (C6-18)aryl or
- (C6-18)aryl annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S,
R3 is (C6.i8)aryl one or morefold substituted by
- halogen,
- halo(C1-6)alkyl,
- halo(C1.6)alkoxy, - cyano,
- phenyl,
- heterocyclyl having 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, S.
2. A compound of claim 1 wherein Rt is methyl, R2 is methyl or methyl substituted by
- quinolinyl,
- benzo[1 ,3]dioxolyl,
- phenyl
- phenyl one or morefold substituted by halogen, halo(CM)alkyl, (CM)alkoxy, cyano, amino, dimethylamino, carboxy(C .2)alkylcarbonylamino, amino(C1.2)alkylcarbonylamino, (C2^)alkylenecarbonylamino, heterocyclylcarbonyl(C1.2)alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, O, - R3 is phenyl one or morefold, e.g. 1- to 3-fold, substituted by
- halogen,
- halo(Ci.2)alkyi,
- halo(Cι-2)alkoxy, - cyano,
- phenyl,
- heterocyclyl, including aromatic, having 6 ring members and 2 nitrogen heteroatoms.
3. A compound of claim 1 or 2 of formula
Figure imgf000038_0001
4. A compound of any one of claims 1 to 3 in the form of a salt.
5. A compound of formula I according to any one of claim 1 to 4 for use as a pharmaceutical.
6. The use of a compound of any one of claims 1 to 4 for the manufacture of a medicament for the treatment of disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1 /JAM-1 interactions.
7. A pharmaceutical composition comprising a compound of formula I according to any one of claim 1 to 4 in association with at least one pharmaceutical excipient.
8. A pharmaceutical composition according to claim 7, further comprising another pharmaceutically active agent. 38
9. A method for treatment of disorders or diseases mediated by LFA-1 /ICAM-1 , LFA-1 /ICAM- 2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I according to any one of claims 1 to 4.
10. A method according to claim 9, wherein a compound of any one of claims 1 to 4 is administerd in combination with another pharmaceutically active agent, either simultanously or in sequence.
IL 12-Dec-2003
PCT/EP2004/000514 2003-01-23 2004-01-22 Diazepanes derivatives useful as lfa inhibitors WO2004065382A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP04704212A EP1590342A1 (en) 2003-01-23 2004-01-22 Diazepanes derivatives useful as lfa inhibitors
US10/541,183 US7419976B2 (en) 2003-01-23 2004-01-22 Diazepanes derivatives useful as IFA inhibitors
NZ540867A NZ540867A (en) 2003-01-23 2004-01-22 Diazepanes derivatives useful as LFA inhibitors
JP2006500007A JP4644655B2 (en) 2003-01-23 2004-01-22 Diazepan derivatives useful as LFA inhibitors
BR0406884-0A BRPI0406884A (en) 2003-01-23 2004-01-22 Diazepans derivatives useful as lfa inhibitors
MXPA05007846A MXPA05007846A (en) 2003-01-23 2004-01-22 Diazepanes derivatives useful as lfa inhibitors.
AU2004205504A AU2004205504B2 (en) 2003-01-23 2004-01-22 Diazepanes derivatives useful as LFA inhibitors
CA002509764A CA2509764A1 (en) 2003-01-23 2004-01-22 Diazepanes derivatives useful as lfa inhibitors
NO20053911A NO20053911L (en) 2003-01-23 2005-08-22 Diazepine derivatives useful as LFA inhibitors.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0301561A GB0301561D0 (en) 2003-01-23 2003-01-23 Organic compounds
GB0301561.7 2003-01-23
GB0323976.1 2003-10-13
GB0323976A GB0323976D0 (en) 2003-10-13 2003-10-13 Organic compounds

Publications (1)

Publication Number Publication Date
WO2004065382A1 true WO2004065382A1 (en) 2004-08-05

Family

ID=32773971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000514 WO2004065382A1 (en) 2003-01-23 2004-01-22 Diazepanes derivatives useful as lfa inhibitors

Country Status (19)

Country Link
US (1) US7419976B2 (en)
EP (1) EP1590342A1 (en)
JP (1) JP4644655B2 (en)
KR (1) KR20050095618A (en)
AR (1) AR042740A1 (en)
AU (1) AU2004205504B2 (en)
BR (1) BRPI0406884A (en)
CA (1) CA2509764A1 (en)
CO (1) CO5580804A2 (en)
EC (1) ECSP055917A (en)
MX (1) MXPA05007846A (en)
MY (1) MY141850A (en)
NO (1) NO20053911L (en)
NZ (1) NZ540867A (en)
PE (1) PE20040941A1 (en)
PL (1) PL376540A1 (en)
RU (1) RU2347783C2 (en)
TW (1) TWI311557B (en)
WO (1) WO2004065382A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111371A1 (en) * 2005-04-19 2006-10-26 Novartis Ag Pharmaceutically active diazepanes
JPWO2006059801A1 (en) * 2004-12-02 2008-06-05 アスビオファーマ株式会社 7-membered ring compounds and their production and pharmaceutical use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2424549B1 (en) * 2009-04-28 2014-04-23 Optmed, Inc. Compositions and methods for treating or preventing urolithiasis and conditions associated therewith

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027102A1 (en) * 1999-10-13 2001-04-19 Novartis Ag Substituted diazepanes
WO2002028842A2 (en) * 2000-10-02 2002-04-11 Novartis Ag Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399599B1 (en) * 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes
AU2002248142B2 (en) 2000-11-28 2007-11-01 Genentech, Inc. LFA-1 antagonist compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027102A1 (en) * 1999-10-13 2001-04-19 Novartis Ag Substituted diazepanes
WO2002028842A2 (en) * 2000-10-02 2002-04-11 Novartis Ag Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOMPONG WATTANASIN: "1,4-Diazepane-2-ones as novel inhibitors of LFA-1", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 3, 9 September 2002 (2002-09-09), pages 499 - 502, XP002277292 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006059801A1 (en) * 2004-12-02 2008-06-05 アスビオファーマ株式会社 7-membered ring compounds and their production and pharmaceutical use
JP2012121898A (en) * 2004-12-02 2012-06-28 Daiichi Sankyo Co Ltd 7-membered cyclic compound, and production method and pharmaceutical application of the same
JP5004590B2 (en) * 2004-12-02 2012-08-22 第一三共株式会社 7-membered ring compounds and their production and pharmaceutical use
US8507714B2 (en) 2004-12-02 2013-08-13 Daiichi Sankyo Company, Limited 7-membered ring compound and method of production and pharmaceutical application thereof
WO2006111371A1 (en) * 2005-04-19 2006-10-26 Novartis Ag Pharmaceutically active diazepanes
JP2008538357A (en) * 2005-04-19 2008-10-23 ノバルティス アクチエンゲゼルシャフト Pharmaceutically active diazepan
EP2206704A1 (en) * 2005-04-19 2010-07-14 Novartis AG Pharmaceutically active diazepanes

Also Published As

Publication number Publication date
MY141850A (en) 2010-07-16
US20060148780A1 (en) 2006-07-06
RU2347783C2 (en) 2009-02-27
PE20040941A1 (en) 2005-01-24
JP4644655B2 (en) 2011-03-02
KR20050095618A (en) 2005-09-29
BRPI0406884A (en) 2006-01-03
US7419976B2 (en) 2008-09-02
JP2006515335A (en) 2006-05-25
CA2509764A1 (en) 2004-08-05
AR042740A1 (en) 2005-06-29
RU2005126459A (en) 2007-02-27
TW200418817A (en) 2004-10-01
NZ540867A (en) 2007-09-28
EP1590342A1 (en) 2005-11-02
MXPA05007846A (en) 2006-02-10
ECSP055917A (en) 2005-11-22
CO5580804A2 (en) 2005-11-30
TWI311557B (en) 2009-07-01
NO20053911L (en) 2005-10-24
AU2004205504A1 (en) 2004-08-05
AU2004205504B2 (en) 2007-09-20
NO20053911D0 (en) 2005-08-22
PL376540A1 (en) 2006-01-09

Similar Documents

Publication Publication Date Title
JP6942853B2 (en) Diazanaphthalene compounds as JAK kinase inhibitors
CN110352188B (en) Fluoroallylamine derivatives and use thereof
JP5148646B2 (en) Cycloalkyl inhibitors of potassium channel function
RU2296751C2 (en) Derivatives of bipiperidine and pharmaceutical composition based on thereof
JP2019520330A (en) Benzazepine dicarboxamide compounds having a secondary amide group
JP5340736B2 (en) Benzamide compounds useful as histone deacetylase inhibitors
EP2986611B1 (en) Certain protein kinase inhibitors
WO1999031073A1 (en) Novel pyrimidine-5-carboxamide derivatives
WO2005107760A1 (en) Compounds and compositions as inducers of keratinocyte differentiation
US6432987B2 (en) Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action
US6753340B2 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as PDE7 inhibitors
CZ147392A3 (en) Novel derivatives of 3-aminopyridazines, acting on a central nervous system, process of their preparation and pharmaceutical preparations in which said derivatives are comprised
EP1154988B1 (en) Mevinolin derivatives
KR20030092008A (en) Peptide deformylase inhibitors
EP1874739B1 (en) Pharmaceutically active diazepanes
WO2001027102A1 (en) Substituted diazepanes
US6627647B1 (en) Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
JP2001055378A (en) New heterocyclic carboxamide derivative
AU2004205504B2 (en) Diazepanes derivatives useful as LFA inhibitors
ZA200504672B (en) Diazepanes derivatives useful as LFA inhibitors
NZ534229A (en) Phenylpyrimidine amines as ige inhibitors
WO1997002254A1 (en) Quinazoline derivatives
CA3181590A1 (en) Substituted isoquinolinylmethyl amides, analogues thereof, and methods using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004704212

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005/04672

Country of ref document: ZA

Ref document number: 200504672

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2509764

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 540867

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 169361

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2006148780

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10541183

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004205504

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048021638

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 376540

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 1654/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020057013432

Country of ref document: KR

Ref document number: 1-2005-501346

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006500007

Country of ref document: JP

Ref document number: PA/a/2005/007846

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 05072726

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2004205504

Country of ref document: AU

Date of ref document: 20040122

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004205504

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200501116

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2005126459

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057013432

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004704212

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0406884

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10541183

Country of ref document: US